 Connection
Kathryn Hassell to Treatment Outcome
This is a "connection" page, showing publications Kathryn Hassell has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.128 |
|
|
|
-
Schofield JR, Hughes HN, Birlea M, Hassell KL. A trial of antithrombotic therapy in patients with refractory migraine and antiphospholipid antibodies: A retrospective study of 75 patients. Lupus. 2021 Apr; 30(4):568-577.
Score: 0.070
-
Kiser TH, Burch JC, Klem PM, Hassell KL. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia. Pharmacotherapy. 2008 Sep; 28(9):1115-24.
Score: 0.030
-
Luchtman-Jones L, Pressel S, Hilliard L, Brown RC, Smith MG, Thompson AA, Lee MT, Rothman J, Rogers ZR, Owen W, Imran H, Thornburg C, Kwiatkowski JL, Aygun B, Nelson S, Roberts C, Gauger C, Piccone C, Kalfa T, Alvarez O, Hassell K, Davis BR, Ware RE. Effects of hydroxyurea treatment for patients with hemoglobin SC disease. Am J Hematol. 2016 Feb; 91(2):238-42.
Score: 0.012
-
Vichinsky E, Bernaudin F, Forni GL, Gardner R, Hassell K, Heeney MM, Inusa B, Kutlar A, Lane P, Mathias L, Porter J, Tebbi C, Wilson F, Griffel L, Deng W, Giannone V, Coates T. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol. 2011 Aug; 154(3):387-97.
Score: 0.009
-
Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL, Okpala I, Ressayre-Djaffer C, Alberti D, Holland J, Marks P, Fung E, Fischer R, Mueller BU, Coates T. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007 Feb; 136(3):501-8.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|